[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cocaine-use-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cocaine-use-disorder":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,45,72,93,113,144,180,204,233,260,289,313,333,358,385,409,439,478],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100602135","impact-of-cocaine-use-and-withdrawal-on-sleep-100602135",false,"NCT07119567","Impact of Cocaine Use and Withdrawal on Sleep","Longitudinal Exploration of Subjective and Objective Sleep Characteristics in Patients With Cocaine Use Disorder During the Withdrawal Process","CokeSo","Inclusion Criteria:\n\n* Male or female, aged 18 years or older\n* Meeting DSM-5 criteria for cocaine use disorder\n* Positive urine drug screen for cocaine\n* Scheduled for inpatient supervised cocaine detoxification within the next four weeks\n* Covered by a national health insurance plan or social security system\n* Have a valid, personal means of contact (telephone or email address) enabling remote follow-up at 6 months.\n\nExclusion Criteria:\n\n* Current diagnosis of opioid use disorder or other psychostimulant use disorders (e.g., amphetamines, methamphetamines, cathinones, methylphenidate)\n* Unstable psychiatric disorder or somatic illness deemed incompatible with study participation by the investigator\n* Current treatment with methylphenidate, modafinil, solriamfetol, melatonin, pitolisant, naltrexone, or bupropion\n* Patients under legal guardianship\n* Pregnant or breastfeeding women: a pregnancy test will be performed prior to inclusion for women of childbearing potential\n* Individuals deprived of liberty by judicial or administrative decision","ALL","18 Years",{"count":20,"type":21},32,"ESTIMATED","OBSERVATIONAL","This study investigates how cocaine use and withdrawal affect sleep and circadian rhythms in individuals undergoing inpatient detoxification. Using wearable sleep monitors, actigraphy, questionnaires, and hormonal biomarkers, it aims to capture both objective and subjective changes in sleep across three key stages: active use, early withdrawal, and late withdrawal. The study is unique in its ability to explore sleep microstructure, the circadian system's role via melatonin and cortisol measurements, and the dynamic relationship between subjective sleep perception and objective sleep data. It also examines whether sleep quality may serve as a predictive marker of long-term withdrawal success.",[25],"Cocaine Use Disorder",[27,28,29,30,31],"Cocaine use disorder","Withdrawal","Sleep","Polysomnography","Actimetry","RECRUITING","2026-06-10",{"date":35,"type":36},"2026-06-11","ACTUAL",{"date":38,"type":36},"2026-03-19",{"date":40,"type":21},"2028-12-31",{"name":42,"class":43},"Hôpital le Vinatier","OTHER",3,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100440166","early-phase-1-c-11npa-pet-amphetamine-in-cocaine-use-disorders-100440166","NCT05011760","[C-11]NPA PET-amphetamine in Cocaine Use Disorders","[C-11]NPA PET-amphetamine in Cocaine Use Disorders (Aim 2)","Inclusion Criteria:\n\n1. Males or females between 18 and 55 years old\n2. Fulfil DSM-5 criteria for cocaine use disorder\n3. No other current DSM-5 psychiatric or addictive disorders (such as major depressive disorder, bipolar disorders, psychotic disorders, etc.,)\n4. No current abuse (six months) of opiates, sedative-hypnotics, amphetamines, and MDMA as well as moderate to severe alcohol or cannabis use (twice a week). Nicotine use will be quantified and controlled between groups using the Fagerstrom Test for Nicotine Dependence (Heatherton et al., 1991);\n5. Not currently on prescription medical or psychotropic medications\n6. No current or past severe medical, endocrine or neurological illnesses including glaucoma, seizure disorders, hypertension, hypercholesterolemia as assessed by a complete medical history and physical\n7. Not currently pregnant or breastfeeding\n8. No history of significant radioactivity exposure in past year from another research study or occupation that exceeds RDRC guidelines\n9. No metallic objects in the body that are contraindicated for MRI\n10. No baseline BP ≥ 140\u002F90 and\u002For HR ≥ 100.\n11. No first-degree relative with an MI or stroke prior to middle age\n12. No first-degree relative with psychosis or mania.\n13. Completed a baseline \\[11C\\]NOP-1A PET scan in Aim 1 (Study Record: Imaging CRF X NOP interactions in Cocaine Use Disorders)","55 Years",{"count":54,"type":21},30,"INTERVENTIONAL",[57],"EARLY_PHASE1","This study uses \\[11C\\]NPA positron emission tomography (PET) and a d-amphetamine challenge to image amphetamine induced dopamine release in the striatum in subjects with cocaine use disorders (CUD). Amphetamine-induced dopamine release data from this study will be correlated with \\[11C\\]NOP-1A VT measured at baseline in the midbrain. \\[11C\\]NOP-1A PET data will be used from aim 1 (see, Study Record: Imaging CRF X NOP interactions in Cocaine Use Disorders)",[25],[61],"[C-11]NOP-1A, [C-11]NPA , nociceptive opioid peptide receptors, dopamine release","2026-06-06",{"date":64,"type":36},"2026-06-09",{"date":66,"type":36},"2021-01-31",{"date":68,"type":21},"2028-09-01",{"name":70,"class":43},"Rajesh Narendran",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":80,"targetDuration":4,"studyType":55,"phases":82,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":92,"locationsCount":71},"100439888","early-phase-1-imaging-crf-x-nop-interactions-in-cud-100439888","NCT05008146","Imaging CRF X NOP Interactions in CUD","Imaging Corticotrophin-releasing Factor (CRF) X Nociceptive Opioid Peptide (NOP) Interactions in Cocaine Use Disorders (Aim 1)","Cocaine use disorders (CUD)\n\n1. Males or females between 18 and 55 years old\n2. Fulfil DSM-5 criteria for cocaine use disorder\n3. No other current DSM-5 psychiatric or addictive disorders (such as major depressive disorder, bipolar disorders, psychotic disorders, etc.,)\n4. No current abuse (six months) of opiates, sedative-hypnotics, amphetamines, MDMA, etc., as well as moderate to severe alcohol or cannabis use (twice a week). Nicotine use will be quantified and controlled between groups using the Fagerstrom Test for Nicotine Dependence (Heatherton et al., 1991);\n5. Not currently on prescription medical or psychotropic medications\n6. No current or past severe medical, endocrine or neurological illnesses including glaucoma, seizure disorders, hypertension, hypercholesterolemia as assessed by a complete medical history and physical\n7. Not currently pregnant or breastfeeding\n8. No history of significant radioactivity exposure in past year from another research study or occupation that exceeds RDRC guidelines\n9. No metallic objects in the body that are contraindicated for MRI\n\nHealthy Controls (HC)\n\n1. Males or females between 18 and 55 years old\n2. No present or past DSM-5 disorders (other than nicotine dependence)\n3. Criteria 5 to 9 as listed previously.",true,{"count":81,"type":21},80,[57],"This study uses \\[11C\\]NOP-1A positron emission tomography (PET) and a hydrocortisone challenge to image the interaction between nociceptive opioid peptide (NOP) receptors and cortisol\u002Fcorticotrophin releasing factor (CRF) in subjects with cocaine use disorders (CUD) and matched healthy controls (HC). It will also examine whether alterations in CRF x NOP interactions predict relapse in subjects with CUD.",[25],[27,86,87],"[C-11]NOP-1A PET","Nociceptive opioid peptide receptors",{"date":64,"type":36},{"date":90,"type":36},"2020-12-31",{"date":68,"type":21},{"name":70,"class":43},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":79,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":100,"targetDuration":4,"studyType":55,"phases":101,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":71},"100599615","early-phase-1-cocaine-and-pentoxifylline-bed-in-47-100599615","NCT07086794","Cocaine and Pentoxifylline (BED IN 47)","Targeting Immune Inflammation in Cocaine Use Disorder: A Human Laboratory Study With Pentoxifylline","Inclusion Criteria:\n\n1. able to speak\u002Fread English,\n2. not seeking treatment for drug use at the time of the study,\n3. female or male between the ages of 18 and 55 years,\n4. recent smoked or intravenous cocaine use verified by benzoylecgonine positive urine, as well as fulfillment of DSM-5 diagnostic criteria for CUD,\n5. judged to be medically and psychiatrically healthy by study physicians other than the diagnosis for CUD at the time of screening,\n6. ECG, read by a cardiologist, within normal limits,\n7. females using an effective form of birth control and not pregnant or breastfeeding and 8) no known contraindications or allergies to pentoxifylline.\n\nExclusion Criteria:\n\n1. unable to speak\u002Fread English,\n2. seeking treatment for drug use,\n3. under 18 years or over 55 years,\n4. no recent smoked or intravenous cocaine use as indicated by benzoylecgonine negative urine and no DSM-5 diagnosis of CUD,\n5. judged to be medically or psychiatrically unhealthy by study physicians at the time of screening,\n6. ECG, read by a cardiologist, outside normal limits,\n7. females not using an effective form of birth control or pregnant or breastfeeding,\n8. contraindications or allergies to pentoxifylline, and\n9. Self-reported history of head trauma, seizure, CNS tumors, or use of concomitant medications that lower seizure threshold, or first-degree family history of seizures.",{"count":54,"type":21},[57],"This will be a human laboratory study evaluating the influence of pentoxifylline treatment on the effects of cocaine. Supported by and included in the Helping to End Addiction Long-term® (HEAL) Initiative.",[25],"2026-06-05",{"date":106,"type":36},"2026-06-08",{"date":108,"type":36},"2025-11-10",{"date":110,"type":21},"2028-02-28",{"name":112,"class":43},"William Stoops",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":55,"phases":122,"briefSummary":124,"conditions":125,"keywords":126,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":71},"100479972","phase-2-efficacy-and-safety-of-sustained-release-dexamphetamine-in-patients-with-moderate-to-severe-cocaine-use-disorder-100479972","NCT05529927","Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder","Efficacy and Safety of 24 Weeks Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder With Comorbid Opioid Use Disorder - A Multicenter Randomized, Double-blind, Placebo-controlled Study","Inclusion Criteria:\n\n* male and female patients between 18 years and over;\n* actively participating in opioid agonist treatment with oral methadone;\n* with moderate or severe cocaine use disorder according to DSM-5;\n* with regular use of cocaine in the previous month (i.e., ≥8 days\u002Fmonth);\n* with snorting, inhaling or injecting cocaine use as primary route of administration;\n* express the intention to reduce or stop their cocaine use;\n* be able and willing to attend the treatment center for 2 days per week;\n* be able and willing to co-operate with the required study assessments and study procedures; and\n* have provided written informed consent.\n\nExclusion Criteria:\n\n* severe medical (e.g., severe renal or hepatic insufficiency\u002Ffailure) or severe psychiatric problems (e.g. previous or acute severe psychotic episode, acute suicidality, current bipolar disorder);\n* cardiovascular problems: clinically relevant ECG abnormalities suggestive of channelopathy or structural or ischemic heart disease, or a prolonged QTc interval (≥500 msec); moderate to severe hypertension (i.e., SBP\\>140; DBP\\>90); HR\\>100, known coronary artery disease (i.e., angina pectoris, acute myocardiac infarction), known cardiomyopathy, CVA;\n* glaucoma;\n* Gilles-de-la-Tourette syndrome;\n* pheochromocytoma;\n* hyperthyroid status;\n* pregnancy or continued lactation;\n* use of monoamine oxidase inhibitor(s) (MAOI): currently or in the past 14 days;\n* treatment with other prescription psychostimulants that might potentially be effective for stimulant use disorder (i.e., (immediate release) dexamphetamine, lisdexamphetamine, methylphenidate, or modafinil);\n* anticipated need for inpatient treatment (clinical judgement);\n* (expected) inability to complete the 30 weeks study (e.g., planned holidays, expected incarceration or hospitalization);\n* insufficient command of the Dutch language; and\n* current participation in another addiction treatment study.",{"count":121,"type":21},204,[123],"PHASE2","In The Netherlands, each year, about 15 thousand people come into treatment because of problems with cocaine use. There is no approved medication for treatment of cocaine addiction and the psychosocial treatment patients receive is not successful for everyone; many return to treatment several times. There is evidence that agonist (\"replacement\") medications are effective in treating addiction: methadone for heroin addiction; nicotine replacement for smokers. Dexamphetamine is a stimulant medication registered for treatment of ADHD. It may also be effective as agonist treatment for people with cocaine addiction.\n\nIt will be investigated whether sustained-release dexamphetamine in people with cocaine addiction, participating in routine methadone maintenance treatment for their comorbid opioid use disorder, (1) reduces cocaine use and (2) improves their health and quality of life.",[25],[127,128,129,130,131,132,133,134],"cocaine use disorder","sustained-release dexamphetamine","agonist pharmacotherapy","opioid use disorder","methadone maintenance treatment","randomized controlled trial (RCT)","placebo-controlled","double-blind","2026-05-26",{"date":137,"type":36},"2026-05-29",{"date":139,"type":36},"2026-04-22",{"date":141,"type":21},"2029-10",{"name":143,"class":43},"Parnassia Addiction Research Centre",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":17,"minAge":151,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":55,"phases":154,"briefSummary":156,"conditions":157,"keywords":162,"overallStatus":170,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":71},"100514108","rtms-and-cognitive-behavioral-therapy-for-cocaine-use-disorder-100514108","NCT05974202","rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder","Augmenting Cognitive-behavioral Therapy With rTMS of the Medial Prefrontal and Anterior Cingulate Cortices for the Treatment of Cocaine Use Disorder","Inclusion Criteria:\n\n1. Age 22-65;\n2. Able to give informed consent and comply with study procedures;\n3. Meets DSM-5 criteria for current moderate\u002Fsevere CUD and are treatment-seeking;\n4. Used cocaine at least 9 days in the past 28 days, with at least weekly cocaine use;\n5. Agree to no more than moderate alcohol consumption (\\\u003C15 drinks\u002Fweek for men and \\\u003C8 drinks\u002Fweek for women) and to avoid using amphetamine\u002Fmethamphetamine and non-prescribed benzodiazepines or barbiturates; and\n6. Women of childbearing potential must agree to use a method of contraception with proven efficacy and agree to not become pregnant during the study.\n\nExclusion Criteria:\n\n1. Meets DSM-5 criteria for current moderate\u002Fsevere major depressive episode, OCD, bipolar disorder, schizophrenia or any psychotic disorder other than transient psychosis due to substance use;\n2. Hamilton Depression Rating Scale score \\> 17;\n3. Young Mania Rating Scale score \\>10;\n4. Meets DSM-5 criteria for current moderate\u002Fsevere other substance use disorder (aside from tobacco use disorder; physiologic dependence on any other substance other than nicotine, including alcohol, is exclusionary);\n5. Heavy weekly alcohol drinking as defined by an average of \\>14 drinks\u002Fweek for men or \\>7 drinks\u002Fweek for women on average during the past 28 days;\n6. Prior alcohol, benzodiazepine, or barbiturate withdrawal that resulted in hospitalization, medical detoxification, or resulted in seizures or delirium tremens;\n7. More than twice weekly use of non-prescribed medications\u002Fdrugs that may change the seizure threshold, including benzodiazepines, barbiturates, GHB\u002FGBL, amphetamines\u002Fmethamphetamine;\n8. Any other current DSM-5 psychiatric disorder(s) that in the investigator's judgment are unstable, would be disrupted by study procedures, or are likely to require pharmacotherapy or psychotherapy during the study period;\n9. Significant current suicide risk, indicated by either: (1) \"yes\" response on #3, 4, or #5 on the C-SSRS and a psychiatric risk assessment indicating a moderate or high risk of suicide or (2) suicidal behavior in the past 3 months (note: non-suicidal self-injurious behavior is not exclusionary);\n10. Females with a positive urine pregnancy test;\n11. Clinically significant abnormal cardiac functioning per electrocardiogram (ECG) (required for any participant age 60 years and older);\n12. Seizure history including: seizure disorder\u002Fepilepsy, alcohol\u002Fdrug withdrawal seizure, or seizure deemed by the study physician to be related to cocaine intoxication\u002Fwithdrawal (note: febrile seizures are not exclusionary)\n13. Other medical conditions that are relatively contraindicated with TMS (seizure disorders, glaucoma, increased intracranial pressure, severe migraines, stroke, brain lesions, pregnancy or breast-feeding, neurodegenerative disease, meningoencephalitis, intracerebral abscess, parenchymal or leptomeningeal cancers);\n14. Medications that lower seizure threshold and in the opinion of the investigator impose significant seizure risk for the individual (including bupropion, antipsychotics, lithium, anticholinergics, and tricyclic antidepressants);\n15. Cognitive disorder (MMSE \\\u003C25);\n16. Disqualifying response on the TMS Adult Safety Screen (TASS);\n17. Implanted devices or stimulators (cardiac pacemakers, vagus nerve stimulators, spinal cord stimulators, cochlear implant);\n18. Currently taking ototoxic medications (aminoglycosides, cisplatin);\n19. Metal implants or paramagnetic objects in the body that prohibits MR scanning;\n20. Claustrophobia that prohibits MR scanning; or\n21. Legally mandated (e.g., to avoid incarceration or other penalties) to participate in SUD treatment program.","22 Years","65 Years",{"count":54,"type":21},[155],"NA","The goal of this clinical trial is to compare the effects of active repetitive transcranial magnetic stimulation (rTMS) to sham (placebo) rTMS prior to cognitive-behavioral therapy (CBT) as a treatment for adults with cocaine use disorder. The main questions it aims to answer are:\n\n* Is rTMS safe and feasible as an augmentation for CBT for the treatment of cocaine use disorder?\n* What is the brain mechanism of rTMS?\n* Will active rTMS (compared to sham rTMS) followed by CBT help adults with cocaine use disorder achieve abstinence from cocaine?\n\nParticipants will:\n\n* Have two brain MRI scans;\n* Undergo 3 weeks of daily rTMS (or sham) treatments (15 sessions), and;\n* Have 12 weeks of once-weekly cognitive-behavioral therapy for the treatment of cocaine use disorder.\n\nResearchers will compare active (real) rTMS to sham (placebo) rTMS. All participants will receive cognitive-behavioral therapy.\n\nThe former principle investigator, Dr. Derek Blevins, has vacated his position (February 2025), and has transferred the principle investigator role to Dr. John Mariani, the STARS Clinic Director.",[158,159,25,160,161],"Cocaine Use","Cocaine Dependence","Cocaine Use Disorder, Moderate","Cocaine Use Disorder, Severe",[163,164,165,166,167,168,169],"Repetitive transcranial magnetic stimulation","rTMS","TMS","Cognitive behavioral therapy","CBT","Functional magnetic resonance imaging","fMRI","NOT_YET_RECRUITING","2026-04-06",{"date":173,"type":36},"2026-04-07",{"date":175,"type":21},"2026-05-01",{"date":177,"type":21},"2028-04-28",{"name":179,"class":43},"New York State Psychiatric Institute",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":55,"phases":189,"briefSummary":190,"conditions":191,"keywords":192,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":71},"100610466","phase-2-repurposing-semaglutide-for-the-treatment-of-cocaine-use-disorder-100610466","NCT07227948","Repurposing Semaglutide for the Treatment of Cocaine Use Disorder","Repurposing Semaglutide for the Treatment of Cocaine Use Disorder: a Pilot Mechanistic Study","Inclusion Criteria:\n\n* Ability to provide informed consent before any study-related activity, willing to comply with all study procedures, and be available for the duration of the study.\n* Meet Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM 5) diagnostic criteria for CUD and report recent cocaine use (verified by at least one positive urine drug screen (UDS) for the cocaine metabolite benzoylecgonine (BE), during intake).\n* Have body mass index (BMI) of ≥25 kg\u002Fm2\n* Agree (if the participant is female and of child-bearing potential) to use effective contraceptive methods, unless the participant's male partner(s) is surgically sterile (underwent vasectomy). Acceptable contraceptives include oral contraceptives, contraceptive sponge, patch, double barrier (diaphragm\u002Fspermicidal or condom\u002Fspermicidal), intrauterine contraceptive system, etonogestrel implant, medroxyprogesterone acetate contraceptive injection, complete abstinence from sexual intercourse, and\u002For hormonal vaginal ring. Contraceptive measures sold for emergency use after unprotected sex are not acceptable methods for routine use. Women of child-bearing potential must provide negative urine pregnancy test prior to randomization. Note: A woman is considered fertile (of childbearing potential) following menarche and until becoming postmenopausal unless permanently sterile. Women in the following categories are not considered a woman of childbearing potential: premenarcheal, premenopausal female with one of the following: documented hysterectomy, documented bilateral salpingectomy, documented bilateral oophorectomy. Postmenopausal female is defined as no menses for 12 months without an alternative medical cause. Females on HRT and whose menopausal status is in doubt will be required to use one of the nonhormonal highly effective contraception methods if they wish to continue their hormone replacement therapy (HRT) during the trial.\n* Have a medical and psychiatric history and a brief physical examination demonstrating no clinically significant contraindications for study participation, in the judgment of the Study Physician and the Principal Investigator.\n* Be able to provide the names of at least 2 persons who can consistently locate their whereabouts.\n\nExclusion Criteria:\n\nMedical Exclusions\n\n* Personal or first-degree relative(s) history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).\n* History or presence of chronic pancreatitis or recent acute pancreatitis.\n* Type 1 or type 2 diabetes mellitus (previously diagnosed or indicated by HbA1C ≥48 mol\u002Fmol (6.5%) as measured at screening).\n* Severe gastrointestinal disease (i.e., severe gastroparesis).\n* History of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed.\n* History of severe cardiovascular disease.\n* History of retinopathy.\n* Systolic blood pressure (SBP) \\>180 mmHg and\u002For diastolic blood pressure (DBP) \\>105 mmHg)\n* End stage renal disease (ESRD, previously diagnosed or indicated by estimated glomerular filtration rate (eGFR) value of eGFR \\\u003C 15 ml\u002Fmin\u002F1.73 m2 at screening).\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3 times the upper limit of normal range at screening.\n* Known or suspected hypersensitivity to semaglutide, excipients, or related products.\n* History of seizure or elevated risk of seizure.\n* Women who are currently pregnant, or plan to become pregnant, or lactating, or of childbearing potential and are not using medically accepted forms of contraception\n* Have any medical illness or condition which in the opinion of the PI and\u002For the Study Physician would preclude safe and\u002For successful completion of the study.\n* Any foreseeable procedure requiring general anesthesia or deep sedation.\n\nPsychiatric\u002FSubstance Use Exclusions\n\n* Current ≥ moderate substance use disorder aside from alcohol, nicotine, or marijuana, or a Substance Use Disorder (SUD) requiring medical detoxification (e.g., alcohol, opioid, benzodiazepine)\n* Current or recent suicidal ideation.\n* Homicidal ideation that requires immediate attention.\n* Have any psychiatric illness or condition which in the opinion of the PI and\u002For the Study Physician would preclude safe and\u002For successful completion of the study.\n\nWeight-Related Exclusions\n\n* Gained\u002Flost ≥4.5 kg (10 lb.) over the past 6 months (prior to screening).\n* Uncontrolled thyroid disease at screening\n\nMedication-Related Exclusions\n\n* Currently using sincalide, sulfonylureas, insulin and insulin products, or medication used for weight management (i.e., orlistat, naltrexone-bupropion, liraglutide, semaglutide, tirzepatide, phentermine, topiramate, benzphetamine, diethylpropion, phendimetrazine).\n* Any otherwise not specified concomitant medication that could compromise participant safety or treatment in the opinion of the Study Physician and\u002For the PIs.\n\nGeneral Exclusions\n\n* Current, anticipated, or pending enrollment in another addiction treatment program and\u002For research study that could potentially affect participant safety and\u002For the study data\u002Fdesign as determined by the Principal Investigator and\u002For Study Physician.\n* Not planning to live in the area for the duration of the trial.\n* Surgery scheduled for the duration of the trial, except for minor surgical procedures, in the opinion of the PI and\u002For the Study Physician.\n* Unable to communicate (read, write, and speak) fluently in English.",{"count":188,"type":21},75,[123],"The purpose of this study is to evaluate semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), in combination with cognitive behavioral therapy (CBT) for the treatment of cocaine use disorder (CUD). This project is part of the NIH Helping to End Addiction Long-term (HEAL) initiative (https:\u002F\u002Fheal.nih.gov\u002F).",[25],[193,194,195],"semaglutide","GLP-1 agonist","cocaine addiction","2026-03-16",{"date":38,"type":36},{"date":199,"type":36},"2026-01-15",{"date":201,"type":21},"2029-02-28",{"name":203,"class":43},"The University of Texas Health Science Center, Houston",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":211,"enrollmentInfo":212,"targetDuration":4,"studyType":55,"phases":214,"briefSummary":215,"conditions":216,"keywords":218,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":71},"100617427","transcranial-direct-current-stimulation-tdcs-for-treatment-of-cocaine-use-disorder-100617427","NCT07318480","Transcranial Direct Current Stimulation (tDCS) for Treatment of Cocaine Use Disorder","Cognitively-enhanced tDCS of the Dorsolateral Prefrontal Cortex to Reduce Craving in Cocaine Addiction","Inclusion Criteria:\n\n* Ability to understand and give informed consent\n* Men and women 18-60 years of age.\n* For women of childbearing potential, current use of a medically acceptable form of birth control\n* DSM-5 diagnosis of stimulant use disorder with crack\u002Fcocaine as the drug of choice\n\nExclusion Criteria:\n\n* Lifetime diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, bipolar I disorder, or delusional disorder as confirmed by the MINI or autism spectrum disorder as confirmed by medical history at the screening visit\n* Current clinically significant or unstable medical conditions, including metabolic, endocrinological, oncological or autoimmune diseases, infectious diseases common in people with substance use disorders including Hepatitis B and C or HIV\u002FAIDS; use of medications deemed exclusionary by the study team; or any laboratory value outside the reference range that the senior investigator team considers to be of clinical relevance\n* Head trauma with loss of consciousness (\\>30 min)\n* History of neurological or developmental disease of central origin including stroke, brain tumor or seizures, encompassing those symptoms associated with periods of drug withdrawal or abstinence\n* Metal implants or devices that may be impacted by the electrical stimulation and additional MR contraindications\n* Women of childbearing potential must use a medically acceptable birth control method during the study and will be asked to take a pregnancy urine test before exposure to tDCS (or MRI)","60 Years",{"count":213,"type":21},120,[155],"The researchers will test whether cognitively enhanced transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex can reduce craving in inpatients with cocaine use disorder. Neuroimaging before and after stimulation will establish the neural correlates of recovery and allow predictions of outcomes, which will be assessed throughout the study and one month after its completion. Results could pave the way towards development of a new self-administered intervention to reduce craving when it is needed the most, enhancing recovery real-time and in the natural environment in people with cocaine addiction as generalizable to other drugs of abuse and other disorders of self-control.",[25,159,217],"Substance Use Disorder (SUD)",[219,220,127,221,222,223],"Transcranial Direct Current Stimulation (tDCS)","Brain Stimulation","drug craving","neuromodulation","neuroimaging","2026-03-02",{"date":226,"type":36},"2026-03-03",{"date":228,"type":36},"2026-02-25",{"date":230,"type":21},"2030-02",{"name":232,"class":43},"Icahn School of Medicine at Mount Sinai",{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":152,"enrollmentInfo":240,"targetDuration":4,"studyType":55,"phases":242,"briefSummary":244,"conditions":245,"keywords":247,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":71},"100617034","phase-4-efficacy-of-clonidine-in-reducing-craving-in-inpatients-with-cocaine-and-crack-use-disorder-100617034","NCT07313371","Efficacy of Clonidine in Reducing Craving in Inpatients With Cocaine and Crack Use Disorder","Efficacy of Clonidine in Reducing Craving in Inpatients With Cocaine and Crack Use Disorder: a Randomized Clinical Trial.","Inclusion Criteria:\n\n* Patients hospitalized in the adult Alcohol and Drugs ward of the Perdizes Institute (IPer) at the Hospital das Clínicas, University of São Paulo Medical School\n* DSM-5 criteria for cocaine and\u002For crack use disorder\n* Voluntarily seeking treatment\n* Must be able to swallow pills\n\nExclusion Criteria:\n\n* Inability to read and\u002For understand the study questionnaires\n* benzodiazepine use disorder\n* opioid use disorder\n* alcohol use disorder",{"count":241,"type":21},36,[243],"PHASE4","This is a single-center, randomized intervention study in a volunteer population of patients with cocaine\u002Fcrack use disorder to evaluate the pharmacological treatment of cocaine\u002Fcrack craving, comparing the drug clonidine with the active placebo clonazepam.",[25,246],"Crack Abuse or Dependence",[248,249,250],"crack","cocaine","craving","2026-02-20",{"date":253,"type":36},"2026-02-24",{"date":255,"type":36},"2026-01-28",{"date":257,"type":21},"2027-07",{"name":259,"class":43},"University of Sao Paulo General Hospital",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":55,"phases":268,"briefSummary":269,"conditions":270,"keywords":276,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":288},"100433670","encouraging-abstinence-behavior-in-a-drug-epidemic-optimizing-dynamic-incentives-100433670","NCT04927143","Encouraging Abstinence Behavior in a Drug Epidemic: Optimizing Dynamic Incentives","Inclusion Criteria:\n\n* Age at least 18 years old;\n* Meet DSM-5 OUD, CoUD, or MUD criteria as evidenced by an OUD CPT code F11\\* (opioid related disorders), a CoUD CPT code F14\\* (cocaine related disorders), a MUD CPT code F15.1\u002FF15.2 or other clinical notes indicating illicit opioid\u002Fcocaine\u002Fmethamphetamine use for treatment\n* Have access to a smartphone (iOS or Android) with data plan and willing to download DynamiCare app;\n* Have an email and can access it from their smartphone;\n* Are in residential, day (PHP), partial day (IOP), or outpatient (OP) AODA treatment;\n* Are likely to be helped by contingency management because at least ONE of the following conditions is true:\n\n  1. Were first enrolled in residential, PHP, or IOP substance use treatment no longer than 2 treatment weeks (14 days\u002Fencounters of treatment) prior to providing informed consent.\n  2. Used non-medical opioids, cocaine, and\u002For methamphetamine within the last 21 days.\n* Understands English.\n\nExclusion Criteria:\n\n* Have evidence of active (non-substance related) psychosis that might impair participation as determined by the PI.\n* Has significant cognitive impairment that might confound participation as determined by the PI or are so significantly cognitively impaired that they have a legal guardian.",{"count":267,"type":21},600,[155],"Combatting the rise of the opioid epidemic is a central challenge of U.S. health care policy. A promising approach for improving welfare and decreasing medical costs of people with substance abuse disorders is offering incentive payments for healthy behaviors. This approach, broadly known as \"contingency management\" in the medical literature, has repeatedly shown to be effective in treating substance abuse. However, the use of incentives by treatment facilities remains extremely low. Furthermore, it is not well understood how to design optimal incentives to treat opioid abuse. This project will conduct a randomized evaluation of two types of dynamically adjusting incentive schedules for people with opioid use disorders or cocaine use disorders: \"escalating\" schedules where incentive amounts increase with success to increase incentive power, and \"de-escalating\" schedules where incentive amounts decrease with success to improve incentive targeting. Both schemes are implemented with a novel \"turnkey\" mobile application, making them uniquely low-cost, low-hassle, and scalable. Effects will be measured on abstinence outcomes, including longest duration of abstinence and the percentage of negative drug tests. In combination with survey data, variation from the experiment will shed light on the barriers to abstinence more broadly and inform the understanding of optimal incentive design.",[271,25,272,158,273,274,275],"Opioid-use Disorder","Opioid Use","Substance Use","Methamphetamine Abuse","Methamphetamine-dependence",[277,278],"contingency management","app-based treatment","2026-02-09",{"date":281,"type":36},"2026-02-12",{"date":283,"type":36},"2021-09-15",{"date":285,"type":21},"2026-09",{"name":287,"class":43},"Wake Forest University Health Sciences",2,{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":55,"phases":299,"briefSummary":300,"conditions":301,"keywords":302,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":288},"100519957","crack-target-1-descriptive-study-of-observed-behavioral-sensitization-and-expectations-100519957","NCT06050304","CRACK-TARGET 1: Descriptive Study of Observed Behavioral Sensitization and Expectations","Descriptive Study of Observed Behavioural Awareness and Patients Expectations of Treatment","CRACK-TARGET","Inclusion Criteria:\n\n* \\> 18 years\n* Have a current crack-cocaine use disorder defined as Severe Intensity Use Disorder (6 or more DSM5 criteria), AND preferential use of rapid administration route (intravenous or smoked)\n* Self-identified male or female (n=10 males, n=10 females)\n* Negative pregnancy test for females and use of effective contraception\n* Be affiliated with a social security plan (or PUMA or CSS or AME)\n* Sign an informed consent and commit to a 3-week follow-up in the study\n* Have a weight greater than 40 kg\n\nExclusion Criteria:\n\n* • Patient with a psychiatric disorder or symptoms that are not currently stabilized\n\n  * Patient who is a minor or under protective supervision (curatorship or guardianship)\n  * Patient in care at the request of a judicial authority (therapeutic injunction, classification with orientation)\n  * Pregnant or breastfeeding women\n  * Patients who do not speak French or English sufficiently\n  * Patients weighing less than 40 kg",{"count":298,"type":21},20,[155],"This research focuses on behavioral sensitization (BS) a specific behavioural disturbance in crack-cocaine addiction. The primary objective is to observe whether BS can be demonstrated in an ecological setting in crack dependent users by continuous actimetry for 3 weeks.\n\nIt is planned to include 20 persons with a current crack-cocaine addiction with a preferential use of rapid administration route (intravenous or smoke), in a care institution: Fernand Widal Hospital.\n\nIn the proposed research, the investigators will assess the movements of crack-cocaine dependent users in relation to consumption. They will have to wear continuously for 3 weeks an actimeter. They will also have 3 blood tests trying to identify biomarkers of BS.",[25],[303,304],"Crack-cocaine","Behavioral Sensitization","2026-01-13",{"date":199,"type":36},{"date":308,"type":36},"2025-03-04",{"date":310,"type":21},"2026-03-04",{"name":312,"class":43},"Assistance Publique - Hôpitaux de Paris",{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":79,"sex":17,"minAge":319,"maxAge":211,"enrollmentInfo":320,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":321,"conditions":322,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":71},"100417877","aberrant-synaptic-plasticity-in-cocaine-use-disorder-a-11c-ucb-j-pet-study-100417877","NCT04721418","Aberrant Synaptic Plasticity in Cocaine Use Disorder: A 11C-UCB-J PET Study","Inclusion Criteria:\n\n* Age 21-60 years\n* Physically healthy by medical history, physical, neurological, ECG and laboratory examinations\n* For females, a negative serum pregnancy test\n* For CUD: DSM-5 criteria for Cocaine Use Disorder and positive urine toxicology showing recent use\n* For HC: Negative urine toxicology\n\nExclusion Criteria:\n\n* DSM-5 criteria for other substance use disorders (e.g., alcohol, opiates, sedative hypnotics), except for nicotine\n* A primary DSM-5 Axis I major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depression, etc.) as determined by the Structured Clinical Interview for DSM-5 (SCID-5)\n* A history of significant and\u002For uncontrolled medical or neurological illness\n* Current use of psychotropic and\u002For potentially psychoactive prescription medications\n* Medical contraindications to MRI procedure","21 Years",{"count":81,"type":21},"The purpose of this research study is to measure synaptic density in the brain comparing individuals with cocaine use disorder to healthy controls.",[25,323],"Healthy Controls","2025-09-09",{"date":326,"type":36},"2025-09-11",{"date":328,"type":36},"2021-07-20",{"date":330,"type":21},"2026-06",{"name":332,"class":43},"Yale University",{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":152,"enrollmentInfo":341,"targetDuration":4,"studyType":55,"phases":343,"briefSummary":344,"conditions":345,"keywords":347,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":288},"100569207","phase-2-evaluation-of-semaglutide-in-adults-with-cocaine-use-disorder-with-and-without-hiv-100569207","NCT06691243","Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV","Evaluation Of Semaglutide Safety and Tolerability in Adults With Cocaine Use Disorder With and Without HIV","STAC","Inclusion Criteria:\n\n1. At least 18 years old\n2. Meet criteria for CUD according to the Diagnostic and Statistical Manual Version 5\n3. Used cocaine at least 7 out of the past 14 days\n4. Body Mass Index between 20 - 50 kg\u002Fm2\n5. English proficiency\n6. In people of childbearing potential, agree to use an acceptable method of birth control\n\nExclusion Criteria:\n\n1. Triglycerides \\> 500 mg\u002FdL\n2. History of gall bladder disease\n3. Personal or family history of medullary thyroid carcinoma, or patients with a history of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)\n4. History of diabetic retinopathy\n5. Being prescribed glucose-lowering medications\n6. An estimated glomerular filtration rate of less than 45 ml\u002Fmin\n7. Lifetime history of taking semaglutide or other GLP-1 RAs\n8. Current suicidal ideation or suicide attempts within the past 24 months\n9. Present diagnosis of diabetes mellitus OR screening hemoglobin A1C \\>\u002F= 6.5\n10. Use of weight-lowering medications\n11. History of gastric bypass surgery\n12. History of myocardial infarction or stroke within the past 12 months\n13. Pregnant, breastfeeding, or the patient intends to become pregnant during the next four months\n14. Any contraindicated medical issues identified by the study investigators\n15. Risk of conditions that are under Warning and Precautions section of OZEMPIC and WEGOVY including but not limited to known history or current report of clinically relevant hypoglycemia, gastroparesis, or pancreatic disease.\n16. Calcitonin value equal to or above 50 ng\u002FL\n17. If completing the MRI portion of the study: claustrophobia or physical issues preventing MRI scan\n18. If completing the MRI portion of the study: presence of a metal device in the body (e.g. pacemaker. Infusion pump, aneurysm clip, metal prosthesis or plate",{"count":342,"type":21},40,[123],"The purpose of this research study is to find out if semaglutide is safe and well tolerated in adults with cocaine use disorder who do and do not have human immunodeficiency virus (HIV). Participants will complete a screening process and if you are able to participate, you will be assigned to one of two treatment groups: semaglutide or placebo.\n\nParticipants will:\n\n* Visit the clinic once a week for semaglutide or placebo injections\n* Visit the clinic once every two weeks for labwork, assessments and\u002For surveys\n* If consented to optional MRI's, complete two MRI's",[25,346],"HIV",[193,348,127],"GLP-1","2025-08-18",{"date":351,"type":36},"2025-08-24",{"date":353,"type":36},"2025-08-07",{"date":355,"type":21},"2027-03",{"name":357,"class":43},"University of Maryland, Baltimore",{"id":359,"slug":360,"hasResults":11,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":152,"enrollmentInfo":365,"targetDuration":4,"studyType":55,"phases":367,"briefSummary":368,"conditions":369,"keywords":370,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":71},"100600006","cocaine-cue-reactivity-incubation-study-100600006","NCT07091877","Cocaine Cue-reactivity Incubation Study","Cognitive Reappraisal for Mitigating Incubation of Cocaine Cue-Reactivity","Inclusion Criteria:\n\n* Ability to understand and give informed consent\n* Age 18-65\n* DSM-5 Diagnosis of CUD (Cocaine Use Disorder)\n* Have appropriate abstinence duration (i.e., \\\u003C2 months) at the first visit.\n* Must be seeking treatment for CUD (at the first visit)\n\nExclusion Criteria:\n\n* DSM-5 diagnosis for other psychiatric illnesses (other than mood and anxiety disorders that are highly comorbid with substance use disorders)\n* Urine positive for any psychoactive drugs (e.g., cocaine, methamphetamine, cannabis, opiates, benzodiazepines, etc.) at baseline\n* Head trauma with loss of consciousness\n* History of neurological diseases, including seizures\n* Thick and\u002For non-removable hair braids that present difficulty for EEG electrode-scalp contact",{"count":366,"type":21},252,[155],"In this study, the research team proposes to longitudinally assess incubation of cue-reactivity, its reduction with cognitive reappraisal (CR; a self-regulation technique) and examine the impact of CR on clinical outcomes in individuals with cocaine use disorder (CUD). The primary objective is to use psychophysiological markers for tracking brain activity and behavior and changes therein with the use of CR during abstinence in CUD. The secondary objective is to examine whether brain and behavioral changes are associated with clinical outcomes in individuals with CUD. The primary endpoint is the time-related change in brain and behavioral indices with CR during abstinence in individuals with CUD. The secondary endpoint is the impact of CR-mediated changes on clinical outcomes of individuals with CUD.\n\nIn this 5-yearlong study the research team will recruit 252 individuals seeking-treatment for CUD, 126 of whom will be randomly assigned to complete the Cognitive Reappraisal task repeatedly at 2 weeks, 1-2 months, 3 months, and 5 months after abstinence initiation (CR+ group), and the other 126 will be assigned to complete a Control task at the same time points (CR- group). All individuals between the ages of 18 and 65 years, irrespective of sex and sexual orientation will be recruited. Participation in the research study will be 5 sessions taking place (one at 2 weeks from screening, one at a month from screening, one at 3 months from screening, one at 5 months from screening, and one the month after the 5 month session) over the course of 6 months.\n\nThe study will include EEG testing and will be administered multiple times over the course of 6 months. Participants will be randomized to one of the two groups; one group will get the Cognitive Reappraisal (CR+) intervention and the other group will get a Control intervention (CR-).",[25],[371,372,373,374,375,376],"Cocaine","Craving","EEG","Cue-reactivity","Cognitive reappraisal","Incubation","2025-07-21",{"date":379,"type":36},"2025-07-29",{"date":381,"type":36},"2024-12-15",{"date":383,"type":21},"2028-08-31",{"name":232,"class":43},{"id":386,"slug":387,"hasResults":11,"nctId":388,"briefTitle":389,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":152,"enrollmentInfo":391,"targetDuration":4,"studyType":55,"phases":392,"briefSummary":393,"conditions":394,"keywords":395,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":71},"100515059","identifying-electrophysiological-targets-for-transcranial-magnetic-stimulation-in-cocaine-use-disorder-100515059","NCT05986578","Identifying Electrophysiological Targets for Transcranial Magnetic Stimulation in Cocaine Use Disorder","Inclusion Criteria:\n\n* non-treatment-seeking adults\n* meet Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria for current cocaine use disorder of at least moderate severity (≥ 4 symptoms)\n* have at least 1 positive urine Benzoylecgonine (BE) specimen (≥ 300 ng\u002FmL) during intake\n* be able to understand the consent form and provide written informed consent\n* be able to provide the following verifiable information for a minimum of 2 contact persons: full legal name,email address, local mailing address, and as applicable, home, work, and cell phone numbers\n\nExclusion Criteria:\n\n* current DSM-5 diagnosis for substance use disorder (of at least moderate severity) other than cocaine, marijuana, or nicotine\n* in the opinion of the principal investigator (PI), the presence of any medical, neurological, psychiatric, or physical condition, disease, or illness that, may: (a) compromise interfere, limit, effect or reduce the subject's ability to complete the study; or (b) adversely impact the safety of the subject or the integrity of the data\n* has current or recent (within 3 months of potential enrollment) suicidal ideation, suicidal behavior, homicidal ideation or a homicidal plan sufficient to raise subject safety concerns based on the following assessments according to the PI:\n\n  1. Structured Clinical Interview for DSM-5 (SCID-5)\n  2. Columbia Suicide Severity Rating Scale (C-SSRS) Screener - Answers YES to Questions 3, 4, 5, or 6\n  3. Assault \\& Homicidal Danger Assessment Tool - Key to Danger \\> 1\n* medical implants contraindicating TMS (i.e., aneurysm clips or coils, stents, implanted stimulators, implanted vagus nerve or deep brain stimulators, implanted electrical devices such as pacemakers or medication pumps electrodes for monitoring brain activity, cochlear implants for hearing, any magnetic implants, bullet fragments, any other metal device or object implanted in your body closer than 30 cm from the coil)\n* history of brain surgery\n* history of an intracranial lesion or any medical or neurological diagnosis\u002Fcondition associated with increased intracranial pressure (i.e., Idiopathic Intracranial Hypertension\u002FPseudotumor Cerebri) OR any of the following symptoms within 30 days of enrollment: headaches \\> 15 days\u002Fmonth, loss of vision or decreased vision\n* moderate-to-severe heart disease\n* history of stroke\n* is taking any antidepressant or antipsychotic medication at a dose above the maximum recommended dose or at a dose deemed to be potentially unsafe according to the PI; has taken any of the following medications, which are known to increase the risk of seizures, within 1 week of study enrollment; or does not agree to abstain from taking the following medications during study participation:\n\n  1. clozapine137\n  2. chlorpromazine137\n  3. bupropion\n  4. clomipramine hydrochloride\n  5. amoxapine\n  6. maprotiline hydrochloride\n  7. diphenhydramine\n  8. stimulants other than cocaine including the following:\n\n     1. Dextroamphetamine and amphetamine\n     2. Dextroamphetamine\n     3. Lisdexamfetamine dimesylate\n     4. Methamphetamine\n     5. Methylphenidate\n  9. tramadol\n  10. isoniazid\n* having conditions of probation or parole requiring reports of drug use to officers of the court\n* personal history of epilepsy or seizure disorder and\u002For family history including a first-degree relative\n* serious head injury with loss of consciousness\n* impending incarceration\n* pregnant or nursing for female patients\n* inability to read, write, or speak English\n* for adolescent aged participants (18-21 only): any risk factor for neurocardiogenic syncope (history of syncope\u002Fpresyncope related to noxious stimuli, anxiety, micturition, or posture)\n* hair style that is incompatible with EEG nets",{"count":188,"type":21},[155],"The purpose of this study is to assess effects of intermittent theta burst stimulation (iTBS) to left dorsolateral prefrontal cortex (dlPFC) and dorsomedial prefrontal cortex (dmPFC) compared to sham on electrophysiological indices of reward sensitivity and motivated attention in adults with cocaine use disorder.",[25],[396,397,398,399,400],"Transcranial Magnetic Stimulation (TMS)","Event-Related Potentials","Substance Use Disorder","Reward Positivity","Late Positive Potential","2025-05-05",{"date":403,"type":36},"2025-05-08",{"date":405,"type":36},"2024-11-08",{"date":407,"type":21},"2028-06-30",{"name":203,"class":43},{"id":410,"slug":411,"hasResults":11,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":417,"targetDuration":4,"studyType":55,"phases":418,"briefSummary":419,"conditions":420,"keywords":421,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":71},"100525693","phase-2-ketamine-and-neurofeedback-training-effects-on-neuroplasticity-in-cocaine-addiction-100525693","NCT06125054","Ketamine and Neurofeedback-Training: Effects on Neuroplasticity in Cocaine Addiction","Boosting and Guiding Neuroplasticity by Combining Ketamine with Neurofeedback-assisted Learning - Towards an Individualized and Integrated Pharmaco-psychotherapy for Cocaine Addiction","Co-Boost","Inclusion Criteria:\n\n* Informed Consent as documented by signature\n* Male and female cocaine users 18 to 55 years of age\n* diagnostic and statisical manual (DSM)-5 diagnosis of CUD\n* Willingness to comply with the study protocol as explained by investigator\n* Normal level of language comprehension (German or Swiss-German)\n\nExclusion Criteria:\n\n* Current or lifetime psychotic disorders\n* History of severe substance-induced psychosis\n* Current or lifetime bipolar I or II disorders\n* Current suicidality\n* Previous suicide attempts during the last 2 years\n* Current severe alcohol use disorder\n* Current severe cannabis use disorder\n* Current moderate or severe stimulant use disorder (other than cocaine)\n* Current moderate or severe benzodiazepine use disorder\n* Current opioid use disorder\n* First-degree relatives with psychotic disorders\n* Beck Depression Inventory Score greater than 25\n* Unmedicated or unstable hypertension\n* Severe illness (e. g. myocardial ischemia or arrythmias, severe pulmonary secretions, glaucoma, congestive heart failure or angina, significant renal or hepatic impairment)\n* Acute infection (e. g. pulmonary or upper respiratory tract infection)\n* Insufficient treated or uncorrected hyperthyroidism\n* Severe central nervous system related traumas or disorders (e. g. stroke, cerebral trauma with loss of consciousness over more than 24h, epilepsy)\n* Increased intracranial pressure\n* Medication directly affecting glutamate signaling (e. g. anticonvulsant medication)\n* Any unstable psychoactive medication (no changes in compounds within last 4 weeks before start of study)\n* Pregnancy or lactation\n* Women of childbearing potential with no use of medically accepted contraceptive (e. g.\n\ncondoms, contraceptive diaphragm, birth control pill, hormone injection, intrauterine device)\n\n* BMI\\>35\n* Allergy, hypersensitivity, or other adverse reaction to previous use of ketamine\n* Contradictions to magnetic resonance imaging\n* Concurrent participation in other clinical study",{"count":213,"type":21},[123],"The goal of this clinical trial is to learn about the effects of the combination of ketamine and realtime functional magnetic resonance imaging (fMRI) neurofeedback training in individuals with cocaine use disorder. The main questions the investigators aim to answer are:\n\n* Can the investigators observe a positive, significant effect on percentage of cocaine use days of both interventions combined as well as stand alone interventions?\n* Is there a significant transfer effect of the neurofeedback training?\n* Is there a significant, ketamine-dependent change in glutamate levels in the nucleus accumbens?\n\nParticipants will be given ketamine and a realtime fMRI neurofeedback training. Both interventions are placebo-controlled. The investigators will compare the four intervention groups to investigate the effects of the stand-alone effects of the intervention and the combination of it.",[25,159],[371,158,422,423,424,425,426,427,428,429],"Ketamine","Reward Sensitivity","Glutamate","Placebo-controlled","Therapeutic effects","Mechanistic effects","Neurofeedback Training","realtime fMRI","2024-12-17",{"date":432,"type":36},"2024-12-20",{"date":434,"type":36},"2024-02-05",{"date":436,"type":21},"2026-03",{"name":438,"class":43},"Dr. med. Marcus Herdener",{"id":440,"slug":441,"hasResults":11,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":445,"eligibilityCriteria":446,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":152,"enrollmentInfo":447,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":449,"conditions":450,"keywords":456,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":71},"100569995","role-of-pavlovian-mechanisms-for-control-over-substance-use-100569995","NCT06701487","Role of Pavlovian Mechanisms for Control Over Substance Use","SFB TRR 265: Losing and Regaining Control Over Drug Intake Work Package 1 of Project B03: General and Specific Pavlovian-to-Instrumental Transfer Effects in a Range of Substance Use Disorders","ReCoDe","Inclusion Criteria:\n\n* Men and women between 18-65 years of age,\n* AUD, and\u002For SUD subjects only: meet 4 or more criteria for DSM-5 alcohol-related and\u002For substance-related (cannabis, amphetamine, methamphetamine or cocaine disorder (not requiring withdrawal as assessed by an independent psychiatrist),\n* Currently using alcohol without a desire for abstinence\n* Ability to consent to the study and complete the questionnaires.\n* Sufficient language(German) and motor skills for using PC\n* existing health insurance\n\nExclusion Criteria:\n\n* Lifetime diagnosis of DSM-5 bipolar disorder or schizophrenia or schizophrenia spectrum disorder (if induced by drugs, it should happen more than a month ago)\n* Current threshold DSM-5 diagnosis of major depressive disorder, or presence of suicidal intention\n* High risk (≤ 26) ASSIST scores in other substances other than alcohol, amphetamine, methamphetamine, cannabis, cocaine, tobacco\n* History of traumatic brain injury or severe neurological disease (such as Dementia, Parkinson's disease, multiple sclerosis, Epilepsy, Meningitis, Stroke)\n* Pregnancy or breastfeeding,\n* Ingestion of medications known to interact with the dopamine system in the 10-day period prior to study participation or less than 4 half-lives after last ingestion (rapid urine test); A detailed list of permitted medication can be added upon request\n* MR contraindications (e.g., pacemakers, metallic or electronic implants, metallic splinters, surgical staples)\n* Color vision deficiency\n* sensorineural hearing loss of 30 dB or greater,\n* Tinnitus and\n* Acute alcohol, substance (cannabis, or methamphetamine, amphetamine, cocaine) intoxication at assessement day verified by breath alcohol tests and drug intoxication verified by rapid urine test.",{"count":448,"type":21},200,"During the first funding period (1st FP), the investigators developed a novel full Pavlovian-to-instrumental transfer (PIT) task that allows assessing both, general and specific PIT to investigate whether specific PIT differs between alcohol use disorder (AUD) and control subjects. Preliminary analyses of the full transfer task indicate that AUD participants exhibit a stronger specific PIT effect compared to controls. Based on these findings, the investigators want to compare specific and general PIT effects in patients with moderate to severe substance use disorders (alcohol, cannabis, methamphetamine, amphetamine and cocaine) to healthy controls on the behavioral and neural level (fMRI).",[451,452,453,454,275,455,25],"Alcohol Use Disorder (AUD)","Alcoholism","Substance Use Disorders","Cannabis Use Disorder","Amphetamine Use Disorder",[217,457,458,455,25,451,459,460,461,462,463,464,465,466,467,468],"Cannabise Use Disorder","Methamphetamine Use Disorder","Pavlovian-to-Instrumental Transfer (PIT)","General Pavlovian-to-Instrumental Transfer","Outcome-specific Pavlovian-to-Instrumental Transfer","Amygdala","Ventral Striatum","Neuroimaging","Humans","Surveys and Questionnaires","Reward","Cues","2024-11-19",{"date":471,"type":36},"2024-11-22",{"date":473,"type":36},"2024-08-05",{"date":475,"type":21},"2027-06-30",{"name":477,"class":43},"Technische Universität Dresden",{"id":479,"slug":480,"hasResults":11,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":486,"targetDuration":4,"studyType":55,"phases":488,"briefSummary":489,"conditions":490,"keywords":491,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":288},"100503305","innovative-cognitive-and-behavioral-psychotherapy-for-cocaine-use-disorder-100503305","NCT05833529","Innovative Cognitive and Behavioral Psychotherapy for Cocaine Use Disorder","Virtual Reality Cue Exposure Therapy for Cocaine Craving: an Innovative Cognitive and Behavioral Psychotherapy for Cocaine Use Disorder (Psychothérapie Innovante COmportementale et Cognitive Pour le Trouble d'Usage de Cocaïne; PICOC)","PICOC","Inclusion Criteria:\n\n* Adult patients (age greater than or equal to 18),\n* Present the diagnostic criteria for a cocaine use disorder (DSM-5; SCID 5-CV),\n* Be voluntarily hospitalized and engaged in a residential standard treatment for cocaine use disorder at the Universitary Hospital of Martinique or at the Hospital Centre of Saint-Esprit in Martinique,\n* Present a motivation of \"action\" or \"maintenance\" of cocaine use cessation (University of Rhode Island Change Assessment Scale),\n* Have been informed of the research,\n* Have given free, informed and express consent,\n* Be affiliated to a social security scheme.\n\nExclusion Criteria:\n\n* Present the diagnostic criteria (MINI 5.0.0.; DSM-IV):\n\n  * Current high suicide risk episode,\n  * Current psychotic syndrome,\n  * Current mania or hypomania episode,\n  * Current post-traumatic stress\n* Present significant symptoms of cyberkinetosis in virtual reality exposure (SP-IE),\n* Present another current medical condition at risk of danger or inability to comply with the protocol (e.g. heart problems, blindness or deafness,...),\n* Be placed under legal safeguard, guardianship or curatorship,\n* Patient who refused to participate in the study,\n* Pregnant or breastfeeding women.",{"count":487,"type":21},54,[155],"Cocaine is the 2nd most used illicit substance in Europe and its use implies numerous health complications as well as an annual social cost of 8.7 G d'€. Classical (picture, video, audio, imagery based or in vivo) cue exposure therapy for substance craving (CET), i.e. the irrepressible and non-voluntary desire to use the substance, failed to prove efficacious in treating substance use disorder. Virtual reality cue exposure therapy for substance craving (VRCET), is more immersive, realistic and controllable, and is suggested as being a more efficacious intervention in reducing craving as compared to classical CET.\n\nSo far it's still not known, thus the secondary aim of the present randomized and clinical trial is to investigate, whether virtual reality cue exposure is more efficacious, as compared to classical cue exposure, in both eliciting and reducing cocaine craving in a clinical context of CET for cocaine craving. The main study aim to is to investigate whether a VRCET for cocaine craving based cognitivo-behavioral therapy (i.e. VRCET followed by memory focused cognitive therapy) is more efficacious than a behavioural therapy (i.e. classical exposure therapy to craving) in reducing cocaine craving.\n\nTo do so, 54 voluntary residential patients in treatment for cocaine use disorder will be recruited from the Universitary Hospital Center of Martinique (CHUM, Martinique, France) and Saint-Esprit Hospital Center (CHSE, Martinique, France) and randomly allocated in either a 3 weeks individual experimental treatment (10 meetings of VRET for cocaine craving followed by 5 meetings of memory focused cognitive therapy) or a 3 weeks individual control treatment (15 meetings of pictures based exposure therapy for cocaine craving). Self-reported measures of retrospective (last 14 days) and in virtuo exposure cocaine craving will be collected at the beginning, after 10 days, after 15 days of treatment and 1 month post. Others secondary subjective, urinary and physiological cocaine use related measures will also be collected.",[25],[371,492,372,493,494,495,398],"Virtual Reality Cue Exposure Therapy","Cognitive and Behavioral Therapy","Cue Exposure Therapy","Memory Focused Cognitive Therapy","2024-06-07",{"date":498,"type":36},"2024-06-10",{"date":500,"type":36},"2023-05-01",{"date":502,"type":21},"2025-05",{"name":504,"class":43},"Thomas Lehoux"]